



Announcement Summary

Entity name

INVEX THERAPEUTICS LTD

Applicable security for the return of capital

IXC - ORDINARY FULLY PAID

Announcement Type

New announcement

Date of this announcement

1/11/2023

Return of Capital amount per security

AUD 0.18630000

Trading in the re-organised +securities on an "ex return of capital" basis commences

8/12/2023

Record Date

11/12/2023

Payment Date

18/12/2023

Refer to below for full details of the announcement



Announcement Details

Part 1 - Entity and announcement details

1.1 Name of +Entity

INVEX THERAPEUTICS LTD

1.2 Registered Number Type

ACN

Registration Number

632145334

1.3 ASX issuer code

IXC

1.4 The announcement is☒ New announcement**1.5 Date of this announcement**

1/11/2023

1.6 ASX +Security Code

IXC

ASX +Security Description

ORDINARY FULLY PAID

Part 2 - Cash return of capital approval requirements and dates

2.1 Are any of the below approvals required for the cash return of capital before business day 0 of the timetable?

- Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity required to be given/met before business day 0 of the timetable for the cash return of capital.

☒ Yes**2.1a Approvals****Approval/Condition**

+Security holder approval

Date for determination

5/12/2023

Is the date estimated or actual?☒ Actual****Approval received/condition met?**



Comments

2.2 Is the cash return of capital a selective reduction of capital

☒ No

Part 3 - Cash return of capital timetable and details

3.1 +Record date

11/12/2023

3.1a Effective date of the cash return of capital

6/12/2023

3.2 Does the +entity have quoted options on issue?

☒ No

3.2a Last day for trading in "cum return of capital" +securities. If the entity has quoted options, last day for trading in pre-return of capital quoted options

3.3 Trading in the re-organised +securities on an "ex return of capital" basis commences. If the entity has quoted options and ASX agrees, trading in the quoted options commences on a +deferred settlement basis.

8/12/2023

3.4 +Record Date

11/12/2023

3.4a If the entity has quoted options, first day for the +entity to send holding statements to +security holders notifying them of the change in exercise price for the quoted options they hold.

3.5 Payment date for cash return of capital. If applicable and the +entity has quoted options, +deferred settlement market in options ends. Last day for entity to send holding statements to +security holders notifying them of the change in exercise price for the quoted options they hold and to notify ASX that this has occurred.

18/12/2023

3.5a If the +entity has quoted options, trading in the options starts on a normal T+2 basis

3.5b If the +entity has quoted options, first settlement of trades conducted on a +deferred settlement basis and on a normal T+2 basis

3.6 Currency in which the cash return of capital is made ("primary currency")

AUD - Australian Dollar



3.7 Cash return of capital amount per +security

AUD 0.18630000

Part 4 - Changes to option pricing as a result of the cash return of capital

4.1 Will the cash return of capital affect the exercise price of any +entity-issued options?

☒ No

Part 5 - Further information

5.1 Has the +entity applied for an ATO class ruling relating to this cash return of capital?

☒ No

5.2 Source of funds for cash return of capital

Cash reserves held at bank.

5.3 Further information relating to this cash return of capital

5.4 Additional information for inclusion in the Announcement Summary